Skip to main content

Table 1 Main characteristics of all the studies included in the meta-analysis

From: Prognostic value of systemic inflammatory markers in ovarian Cancer: a PRISMA-compliant meta-analysis and systematic review

Study, (Author/year/Country) Cancer traits Treatment Patients Age, Follow-up, months (Range) Therapy Response/Survival Data NOS Score
Miao/2016/China [10] EOC; Serous papillary histology (n = 216, 62.8%); FIGO stage III (n = 168, 48.8%); platinum-resistant group (n = 96, 27.9%); Comprehensive surgical staging or tumor debulking followed by 6 cycles of adjuvant chemotherapy. 344 55 (45–84) 72 (61-97) PFS (HR)
PLR (cut-off value: 207)
Ua: 3.851 (2.958 to 5.014)
Ma: 1.952 (1.430 to 2.662)
NLR (cut-off value: 3.02)
Ua: 5.093 (3.886 to 6.676)
Ma: 1.733 (1.225 to 2.453)
OS (HR)
PLR (cut-off value: 207)
Ua: 3.863 (2.960 to 5.043)
Ma: 2.167 (1.565 to 3.000)
NLR (cut-off value: 3.02)
Ua: 4.970 (3.794 to 6.511)
Ma: 1.616 (1.138 to 2.297)
9
Wang/2015/China [12] SOC; FIGO stage III-IV (n = 93, 73.8%) Cytoreductive surgery including para-aortic and pelvic lymph node dissection followed by platinum-based chemotherapy. 126 NA 41.3 (3.3–70.4) PFS (HR)
PLR (cut-off value: 187.6)
Ua: 1.306 (0.684–2.495)
Ma: 1.127 (0.433–2.932)
NLR (cut-off value: 2.65)
Ua: 3.191 (1.514–6.728)
Ma: 3.554 (1.389–9.096)
OS (HR)
PLR (cut-off value: 187.6)
Ua: 1.090 (0.510–2.329)
Ma: 1.689 (0.590–4.835)
NLR (cut-off value: 2.65)
Ua: 3.775 (1.497–9.519)
Ma: 5.302 (1.817–15.471
8
Cho/2009/Korea [13] EOC; Serous papillary histology (n = 131, 68.2%); FIGO stage III-IV (n = 125, 65.1%) Treatment according to NCCN guidelines. 192 51.8 ± 12.9 20.9 DFS
P = 0.014
OS (HR)
NLR (cut-off value: 2.6)
Ua: 6.05 (1.77–20.71)
Ma: 8.42 (1.09–64.84)
8
Wang/2016/China [14] OC; EOC (N = 122 85.3%); FIGO stage III-IV (n = 89, 62.2%) NA 143 52.3 ± 14.1   PFS (HR)
PLR (cut-off value: 201)
Ua: 1.43 (0.87–2.35)
Ma: 1.71 (0.80—3.66)
NLR (cut-off value: 3.43)
Ua: 2.11 (1.29–3.46)
Ma: 2.20 (1.03–4.70)
OS (HR)
PLR (cut-off value: 201)
Ua: 1.76 (1.02–3.06)
Ma: 2.05 (0.85–4.95)
NLR (cut-off value: 3.43)
Ua: 2.90 (1.66–5.05)
Ma: 3.37 (1.39–8.15)
8
Asher/2011/UK [15] OC; Serous papillary histology (n = 117, 49.6%); FIGO stage III-IV (n = 141, 60%) Surgery followed by chemotherapy 235 62 (24–90) 24.5 (0.3–191.1) NA OS (HR)
PLR (cut-off value: 300)
Ua: 1.863 (1.37–2.534)
Ma: 1.698 (1.031–2.797)
NLR (cut-off value: 4)
Ua: 1.686 (1.231–2.310)
Ma: 0.865 (0.521–1.437)
7
Williams/2014/USA [16] OC; Serous papillary histology (n = 300, 58%); FIGO stage III-IV (n = 308, 61%) NA 519 ≥55 ys: 56% 68.4 (1-252) NA OS (HR)
NLR (cut-off value: 3.6)
Ua: 1.43 (1.13,1.81)
Ma: 1.37 (1.06, 1.76)
7
Thavaramara/2011/Thailand [17] EOC; FIGO stage III-IV (n = 61, 47.6%) Gynecologic surgery followed by chemotherapy 129 49.6 ± 12.5 NA PFS (HR)
NLR (cut-off value: 2.8)
Ua: NA
Ma: 0.7 (0.3-1.4)
OS (HR)
NLR (cut-off value: 2.8)
Ua: NA
Ma: 0.7 (0.3-1.6)
8
Raungkaewmanee/2014/ Thailand [11] EOC; Serous papillary histology (n = 136, 81.9%); FIGO stage III-IV (n = 78, 47%) Surgery followed by chemotherapy 166 53 (23-85) 28.3 (6.1-94.4) PFS (HR)
PLR (cut-off value: 200)
Ua: 1.89 (1.24–2.88)
Ma: 1.51 (0.88-2.61)
PFS (HR)
NLR (cut-off value: 2.6)
Ua: 1.16 (0.91-1.49)
Ma: NA
OS (HR)
PLR (cut-off value: 200)
Ua: 2.67 (1.43–4.98)
Ma: 1.41 (0.77-2.56)
OS (HR)
NLR (cut-off value: 2.6)
Ua: 1.19 (0.72-1.98)
Ma: NA
9
Feng/2016/ China [18] HGSC; FIGO stage III-IV (n = 800, 91.4%) Primary staging or debulking surgery, and 66.9% patients followed by chemotherapy 875 56 (30–90) 29 (1–115) PFS (HR)
NLR (cut-off value: 3.24)
Ua: NA
Ma: 1.250 (1.052–1.484)
OS (HR)
NLR (cut-off value: 3.24)
Ua: NA
Ma: 1.189 (0.940–1.504)
8
Zhang/2015/ China [19] OC; FIGO stage III-IV (n = 137, 72.1%) cytoreductive surgery followed by platinum-based chemotherapy 190 51 (24–76) 43 (2–164) PFS (HR)
PLR (cut-off value: 203)
Ua: 2.224 (1.626–3.042)
Ma: 1.852 (1.271–2.697)
NLR (cut-off value: 3.4)
Ua: 2.012 1.476–2.741
Ma: NA
OS (HR)
PLR (cut-off value: 203)
Ua: 2.490 (1.758–3.527)
Ma: 2.158 (1.468–3.171)
NLR (cut-off value: 3.4)
Ua: 2.172 (1.545–3.054)
Ma: NA
9
  1. PFS progression-free survival, OS overall survival, CI confidence interval, OC ovarian cancer, EOC epithelial ovarian cancer, HGSC high-grade serous ovarian cancer, HR hazard ratio, NLR neutrophil to lymphocyte ratio, PLR platelet to lymphocyte ratio, ROC receiver operating characteristic, AUC area under curve, SOC serous ovarian cancer, NCCN National Comprehensive Cancer Network, NA none acquired